Articles tagged with: Daratumumab
It’s July, and we have had some time to digest the findings from the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago May 30 through June 3.
Quite a few presentations caught one’s eye.
We finally saw the results of the much awaited PANORAMA-1 study investigating the efficacy and safety of panobinostat (LBH589) plus Velcade and dexamethasone compared to Velcade and dexamethasone alone.
Another study looked at …
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago came to an end yesterday.
The fourth day of the meeting, which was Monday, was the busiest day in regard to myeloma-related research. It started with an oral presentation session that included seven talks about important new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.
This article summarizes the most important findings from Monday’s oral presentation session. A later article will cover the findings from the afternoon poster session.
This year’s American Society of Clinical Oncology (ASCO) annual meeting began yesterday morning in Chicago and will run through Tuesday.
Myeloma-related presentations were made during two sessions yesterday.
One session was designed to better educate physicians about personalized therapy for elderly patients with lymphoid malignancies. During that session, Dr. Tanya Marya Wildes from the Washington University School of Medicine in St. Louis talked about how to navigate treatment options for older multiple myeloma patients.
The key myeloma-related research presented yesterday was made public during a poster session in the afternoon …
The American Society of Clinical Oncology will hold its 50th annual meeting May 30 through June 3 in Chicago.
Similar to previous years, more than 25,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care.
During the meeting, there will be presentations about all areas of cancer, including many focused specifically on multiple myeloma. The ASCO website currently lists information about more than 60 myeloma-related studies (included under either the “multiple myeloma” or “
The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.
Previous years have witnessed research shedding new light on existing myeloma therapies, as well as additional research about potential new therapies.
But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic improvements in the treatment of the disease.
In 2013, not only was there more research about existing therapies, and more …